TURKISH PHARMA GIANT ABDI IBRAHIM KICKS OFF EXPORTS TO AZERBAIJAN AND GEORGIA FROM ITS KAZAKHSTAN FACILITIES FOR PRODUCT DEVELOPMENT AND MANUFACTUR
The leader of the pharmaceutical industry in Turkey, Abdi Ibrahim kicks off exports to Azerbaijan and Georgia from its Kazakhstan company, Abdi Ibrahim Global Pharm, which houses pharmaceutical production facilities. Hepatitis and diabetes products from the largest and most modern pharmaceutical plant in Kazakhstan will be exported to both countries under the assurance of Abdi Ibrahim.
Abdi Ibrahim has maintained its operations incessantly for the last 105 years in order to heal lives and the future through pioneering and innovative initiatives. The company has taken another firm step towards its 2020 targets through its Kazakhstan investment which marks the most significant component in its overseas investment portfolio. Abdi Ibrahim laid the foundations of the Kazakhstan facility in 2013. Soon after the launch of its operations, the production facility was awarded the GMP Certificate, which constitutes a reference document for best practices in manufacturing. The plant represents the largest and most modern pharmaceutical facility in Kazakhstan. Put to life by Abdi Ibrahim upon an investment of 60 million USD, the facility kicked off its operations with a production capacity of 24 million boxes per year. Furthermore, it earned its first international licenses and won the national tender in Georgia and Azerbaijan. Hepatitis and diabetes products manufactured here will be exported to Georgia and Azerbaijan under the quality and assurance of Abdi Ibrahim. Abdi Ibrahim is already solo supplier of several products in these categories Kazakhstan for several years.
The production site, which is built on an indoor space covering 12.000 square meters, employs around 200 people. There are approximately 100 products manufactured in the facility, ranging from key products such as diabetes and antiviral products to cardiovascular products and products used in the treatment of central nervous system diseases.
Abdi Ibrahim International Markets Sales and Marketing Director, Cengiz Zaim shared the following information regarding the company's Kazakhstan investment: "Our plant in Kazakhstan is an indicator of our determination to become a strong brand in international markets; one of our five growth areas that we identified in line with our 2020 strategy. We will initiate our exports to Georgia and Azerbaijan where we have maintained our operations for the last 10 years. Hepatitis and diabetes products to be manufactured in our facility will be exported to these two countries under the assurance of Abdi Ibrahim. In coming years, we aim to export to the countries in Eurasia Customs Union and CIS countries so as to augment our current potential. On the path to 2020, when we target to be in top 100 companies of the world, we will speed up our export activities so as to sustain our growth in the local markets." http://www.marketwatch.com/story/turkish-pharma-giant-abdi-ibrahim-kicks-off-exports-to-azerbaijan-and-georgia-from-its-kazakhstan-facilities-for-product-development-and-manufacturing-2017-04-10